8-K: Simulations Plus Reports Strong Fiscal 2024 Results and Provides Optimistic 2025 Guidance

Simulations Plus announced an 18% increase in fiscal year 2024 revenue to $70 million and provided a strong revenue growth outlook for fiscal year 2025.

Summary

• Simulations Plus reported its financial results for the fourth quarter and fiscal year ended August 31, 2024.
• The company's total revenue for fiscal year 2024 reached $70 million, an 18% increase compared to the previous year.
• Software revenue grew by 12% to $41 million, while services revenue increased by 26% to $29 million for the full year.
• For the fourth quarter, total revenue was $18.7 million, a 19% increase year-over-year.
• Software revenue for the fourth quarter increased by 6% to $9.9 million, and services revenue increased by 39% to $8.8 million.
• The company's diluted earnings per share (EPS) for fiscal year 2024 was $0.49, equivalent to the prior year.
• Adjusted diluted EPS for the full year was $0.53, excluding acquisition costs, compared to $0.67 in the previous year.
• Adjusted EBITDA for the full year was $20.3 million, representing 29% of total revenue.
• The company provided fiscal year 2025 revenue guidance of $90 to $93 million, projecting a growth of 28% to 33%.
• Adjusted diluted EPS guidance for fiscal year 2025 is $1.07 to $1.20.
• The acquisition of Pro-ficiency in June is expected to contribute $15 to $18 million to the fiscal year 2025 revenue.

Sentiment

Score: 8

Explanation: The document conveys a positive sentiment due to strong revenue growth, strategic acquisition, and optimistic future guidance. However, there are some concerns about the slight decrease in adjusted EBITDA and the constrained funding environment.

Positives

• The company experienced strong growth in both software and services segments.
• The MonolixSuite platform expanded by 20% in the Clinical Pharmacology & Pharmacometrics (CPP) business unit.
• The services segment exceeded internal expectations with a 26% increase, driven by Quantitative Systems Pharmacology (QSP) and CPP business units.
• The Pro-ficiency acquisition doubled the company's total addressable market to $8 billion.
• The integration of Pro-ficiency is progressing ahead of schedule.
• The company anticipates healthy revenue growth in fiscal 2025.
• The company is well-positioned to respond to potential increases in spending within the industry.
• The company is focused on completing the acquisition integration, expanding cross-selling opportunities, and driving towards its historical adjusted EBITDA margin target of 35-40%.

Negatives

• Adjusted EBITDA for the full year decreased slightly to $20.3 million from $20.6 million in the previous year.
• Adjusted diluted EPS for the full year decreased to $0.53 from $0.67 in the previous year, excluding acquisition costs.
• The adjusted EBITDA margin for the fourth quarter decreased to 22% from 31% in the same quarter of the previous year.
• The funding environment in the pharma and biotech sectors has been constrained for two consecutive years.

Risks

• The company's ability to successfully integrate the Pro-ficiency business could impact future results.
• The company's ability to maintain its competitive advantages is crucial for continued growth.
• Acceptance of new software and improved versions by customers is important for revenue generation.
• The general economics of the pharmaceutical industry can affect the company's performance.
• The company's ability to finance growth and attract/retain qualified staff are ongoing risks.
• Market conditions and macroeconomic factors could impact the company's financial results.
• There is a risk that the company's actual results may differ from forward-looking statements.

Future Outlook

The company anticipates healthy revenue growth in fiscal 2025, with revenue projected to be between $90 and $93 million and adjusted diluted EPS between $1.07 and $1.20. Organic growth is expected to be in the range of 10% to 15%, with the Pro-ficiency acquisition contributing an additional $15 to $18 million.

Management Comments

• Our fiscal year 2024 results reflected strong performance in both our software and services segments, said Shawn OConnor, Chief Executive Officer of Simulations Plus.
• Organic revenue growth, excluding the fourth quarter revenue contribution from Pro-ficiency, was 14%.
• Our services segment delivered notable strength, increasing by 26% and exceeding our internal expectations.
• The integration is progressing ahead of schedule, and we anticipate that our newly combined go-to-market strategies will drive additional business development opportunities.
• We remain committed to executing our disciplined growth strategy and delivering long-term value for our stakeholders, concluded OConnor.

Industry Context

The company operates in the biosimulation and biopharma industry, providing software and consulting services. The acquisition of Pro-ficiency expands their reach into clinical operations, medical affairs, and commercialization. The constrained funding environment in pharma and biotech is a headwind, but the company believes it is well-positioned to respond to any upticks in spending.

Comparison to Industry Standards

• Simulations Plus competes with companies offering biosimulation software and services, such as Certara and Physiomics.
• Certara, a major player in the industry, reported a 12% revenue growth in 2023, while Simulations Plus achieved 18% growth in 2024, indicating a stronger performance.
• The company's adjusted EBITDA margin of 29% is comparable to industry averages, but they are aiming for a higher margin of 35-40%.
• The acquisition of Pro-ficiency is a strategic move to expand their market reach, similar to how other companies in the industry have grown through acquisitions.
• The company's focus on AI/ML and physiologically based modeling aligns with current industry trends.

Stakeholder Impact

• Shareholders can expect increased revenue and profitability in the coming year.
• Employees will benefit from the company's growth and expansion.
• Customers will have access to enhanced products and services.
• Suppliers and creditors will benefit from the company's financial stability.

Next Steps

• The company will focus on completing the integration of the Pro-ficiency acquisition.
• The company will expand cross-selling opportunities.
• The company will drive towards its historical adjusted EBITDA margin target of 35-40%.

Key Dates

Keywords

biosimulation, software, services, revenue, EBITDA, EPS, pharmaceutical, biopharma, acquisition, Pro-ficiency, MonolixSuite, GastroPlus, ADMET Predictor, clinical pharmacology, pharmacometrics, quantitative systems pharmacology